Hepcidin | ApexOnco - Clinical Trials news and analysis

x

“The team is super responsive to my inquiries and suggestions”

Chief Business Officer

US public biotech company

Click here for more information

Trial results

3 March 2025

Protagonist Verifies Takeda’s interest

Rusfertide, the subject of a 2024 tie-up, scores in phase 3.

Deals

1 February 2024

Takeda taps Protagonist before it’s Verified

Rusfertide’s big readout will now not come until 2025.

Subscribe to Hepcidin